Novo Nordisk reported 168.07B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Bausch Health Companies USD 147M 1.33B Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Merck USD 49.06B 725M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Novo Nordisk 168.07B 29.53B Jun/2025
Novo Nordisk DKK 138.54B 18.02B Mar/2025
Pacira USD 757.77M 40.77M Jun/2025
Sanofi 70.28B 3.8B Jun/2025
Supernus Pharmaceuticals USD 1.06B 33.2M Jun/2025